Apparently the often-low standards for the FDA aren’t low enough. Now we just move trials to poor countries and use control arms that we wouldn’t approve here. VIVIO team member Bishal Gyawali writes about this in the Lancet. Look at the data yourselves and stop listening to the ‘experts’ who are paid to say ‘yes.’
VIVIO clinical team member, Bishal Gyawali, MD, PhD, is part of the team that develops the WHO Essential Medicines List (EML) identifies priority medicines that are most important to public health. Over time, the EML has included an increasing number of cancer medicines. See the details of their ground breaking work.
VIVIO clinical team member, Daniel Goldstein is referenced in Peter Bach’s scathing commentary in Health Affairs on the waste being driven by vial size games played by Pharma. The original article describes how Merck’s increase of vial size has led to billions of dollars of Keytruda being thrown away.
VIVIO clinical team member, Bishal Gyawali, MD, PhD, on why financial toxicity deserves more attention. “The more lung cancer patients had to pay out of pocket for treatment, the less likely they were to adhere to, or continue, therapy, reported researchers, who also found an indication of resulting less-than-ideal survival odds.”
Bishal Gyawali, MD, PhD, VIVIO clinical team member, interviewed. According to Gyawali, “what’s the point in having a drug that does not reach patients because of unaffordability? Both high cost and low probability of clinical benefit should make us question the value of a drug, not hail it as a game-changer.”
Pramod John, PhD, CEO of VIVIO Health, discusses a recent presentation where he spoke about using real-world data to drive better outcomes and lower costs, as well as weighs the benefits of value-based care.